James Flatt, Ph.D., previously served as Executive Vice President of R&D and Operations for Mascoma Corporation, and was its Acting President since August 2009. Jim has also served as Senior Vice President of Research and Development for Martek Biosciences Corp and prior to joining Martek Biosciences, he served as the Vice President of Research and Development for OmegaTech, a DHA producer in Colorado that was acquired by Martek. Jim is the author of six patents and numerous professional papers. He received his B.S. in chemical engineering from the Massachusetts Institute of Technology, his M.S. in chemical engineering from the University of California Berkeley and his Ph.D. in chemical and biochemical engineering from the University of Wisconsin Madison.
James Flatt, CTO
June, 2010. Lonergan Partners is pleased to announce that Jim Flatt has been named Chief Technical Officer of Synthetic Genomics.
About Synthetic Genomics
Synthetic Genomics, Inc. develops and commercializes genomic-driven solutions to address global energy and environmental challenges. The company engages in synthesizing and programming DNA by developing and utilizing the technologies in synthetic genomics. It designs and develops microbes for industrial processes and environmental applications. The company’s solutions help in improving the production of energy, chemicals, and pharmaceuticals, as well as enable carbon sequestration and environmental remediation. Synthetic Genomics, Inc. was founded in 2005 and is based in La Jolla, California.
Jim’s background in biofuels and food science is uniquely suited for the important work that Craig Venter and Synthetic Genomics is doing to turn science into practical solutions.
I’m thrilled to join the talented team at SGI in their quest to solve 21st Century problems using pioneering advanced modern biotechnology solutions.